2Q2024 Medtech Public Company Summary and Valuation Guide
Key Takeaways
-
Market Expectations for 2025: Analysts anticipate a significant increase in earnings per share (EPS) growth, expecting double-digit growth across the board and over 15% growth for diagnostics and consumer health segments in 2025.
-
Medtech Sector Performance: While the medtech sector showed strong performance at the beginning of 2024, valuations experienced a downturn in the second quarter, leading to broad underperformance compared to major indexes.
-
Best and Worst Performers: Natera and Insulet outperformed with gains of 18.4% and 17.8%, respectively, while Illumina, Exact Sciences, and Eurofins saw declines over 20%.
-
M&A Activity: There has been a notable increase in multibillion-dollar acquisitions in the medtech sector, with Axonics and Silk Road Medical being acquired by Boston Scientific. This suggests the market is receptive to M&A deals when the price is fair.
-
IPO Window and M&A Benefits: The limited activity in public takeovers might benefit strategic buyers looking to acquire late-stage medtech startups, potentially leading to more M&A deals.
Stock Returns
- Sources: PitchBook and Morningstar.
- Geography: Global.
- As of June 30, 2024:
- Medical Devices & Supplies
- Life Sciences
- Diagnostics
- Consumer Health
Valuations
- Sources: PitchBook and Morningstar.
- Geography: Global.
- As of March 31, 2024:
Revenue
- Sources: PitchBook and Morningstar.
- Geography: Global.
- As of June 30, 2024:
- Medical Devices & Supplies
- Consumer Health
- Life Sciences
- Diagnostics
EBITDA
- Sources: PitchBook and Morningstar.
- Geography: Global.
- As of June 30, 2024:
- Medical Devices & Supplies
- Consumer Health
- Life Sciences
- Diagnostics
Interactive Excel Data Pack
The comprehensive data pack includes forward-looking estimates and is available to PitchBook clients through the Excel plugin, offering interactive access to financial data and company information for over 55,000 public companies worldwide, along with proprietary data on over 4 million private companies.
新兴技术研究
Medtech公共薪酬表和评估指南
关键要点
PitchBookData,Inc.
NizarTarhuni机构研究和编辑副总裁保罗·康德拉新兴技术研究主管
•分析师对2025年持乐观态度:目前的共识预测表明,与未来几年相比,今年剩余时间的预期存在显著差异。Cosess预计2024年全年各个医疗技术部门的每股收益增长从-3%上升到9%;然而,分析师对明年的看法明显更加乐观。到2025年,分析师预计诊断和消费者健康领域的EPS将全面增长两位数,EPS增长超过15%。全球利率、选举结果以及与商业地产市场相关的尾部风险的不确定路径仍然存在下行风险。尽管如此,我们预计随着通胀放缓,消费者明年可能会体验到更大的购买力,这可能会给消费者健康公司和直接面向消费者的商业模式带来福音。此外,我们预计医疗技术行业将经历一系列成果,一些公司将受益于AI-。
机构研究小组
Aaron DeGagne, CFA高级分析师,Healthcareaaron.degagne@pitchbook.com
诊断和其他公司,如生命科学公司,在更具挑战性的后COVID-19大流行环境中继续寻求增长机会。
•Medtech股票表现不及市场:在2024年上市的medtech股票的强劲开局之后,估值在第二季度有所回落,该行业的表现普遍低于主要指数。从积极的方面来看,Natera和Islet是本季度表现最好的两只医疗科技股,涨幅分别为18.4%和17.8%。在2023年市场对减肥药对糖尿病行业的影响感到恐慌之后,由于投资者对GLP-1s的近期影响进行了折价,Islet等主要糖尿病公司的股票出现反弹。相比之下,该行业第二季度表现最差的是诊断,Illmia、ExactScieces和Erofis的跌幅均超过20%。Illmia的股票仍然受到强制剥离癌症测试子公司Grail的压力,而Grail的分拆终于在6月完成。除了个人名字的股价表现外,所有主要医疗技术板块在第二季度都经历了市场下跌,而标准普尔500指数和纳斯达克指数分别上涨了3.9%和8.3%,这表明投资者最近已经从医疗技术转向其他板块。
Contents
•公开收购接管,更多的并购可能随之而来:尽管对于medtech并购来说,这是一个普遍平静的时期,但最近发生了一些数十亿美元的收购。今年,几家上市公司被大型战略公司收购,包括ShocwaveMedical,Axoics,Abiomed,以及最近的SilRoadMedical。Axoics和SilRoadMedical均被BostoScietific收购,投资者对这些交易反应积极,波士顿的股价年初至今上涨了33%以上。显然,当一个高质量的企业可以以公平的价格购买时,市场会接受并购交易,这可能会导致更多的交易很快越过终点线。与这些对较小公众的收购相反,后期医疗技术初创公司的交易活动水平并不相同,我们部分归因于买家和卖家之间持续的价格差距。尽管如此,如果IPO窗口基本上保持关闭状态,从并购的角度来看,这可能有利于战略,因为初创公司可能更愿意以更合理的倍数被收购。
PitchBookmedtech表格是使用PitchBook和Morningstar数据的PitchBookExcel插件构建的。该工具允许订户将美国和世界上超过55,000家上市公司的财务数据和公司信息,以及PitchBook关于超过400万家私营公司的专有数据提取到Excel中。
股票回报*
PitchBook客户可通过Excel插件获得此报告的完全交互式Excel数据包。
Valuations
PitchBook客户可通过Excel插件获得此报告的完全交互式Excel数据包。
收入*
EBITDA*